FDA Places Clinical Hold on Venetoclax Trials for Multiple Myeloma
This action does not impact currently approved indications for venetoclax.
All articles by Da Hee Han, PharmD
Esperoct Approval Provides New Treatment Option for Hemophilia A
Novo Nordisk announced that the Food and Drug Administration (FDA) has approved Esperoct (turoctocog alfa pegol, N8-GP) for the treatment of patients with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes, on-demand treatment and control of bleeding episodes and perioperative management of bleeding.
Next post in Bleeding Disorders
